Expediting Radioimmune Conjugate Pharmaceuticals for First-In-Human Phase 0 Proof-of-Concept Human Studies from Stable Pool
Experience.
History-Making.
What strategies are being employed to accelerate product development and commercialization without compromising quality?
The Most Significant Regulatory Decision or Guidance on the Horizon for 2024 (or Beyond)?
The Single Most Consequential Event Or Result In Pharma/Biopharma In 2023
Reach the Patient Quicker with GBI’s Manufacturing Solutions
Dr. Muctarr Sesay on AI & Machine Learning in Biopharma RoundTable
VP of Commercial Operations spoke at the BPI Theater at BIO
GBI is pleased to announce that we are swinging hammers on our state-of-the-art commercial facility
Disruptive & Transformational Theranostics Technology – RoundTable Discussion
